BGI Genomics - Public Comps and Valuation Multiples

BGI Genomics Overview

About BGI Genomics

BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.

Founded

2010

HQ

Employees

n/a

Website

bgi.com

Sectors

Genomics & Personalized Medicine
Laboratory Services
BioTech
DeepTech

Financials

LTM Revenue $513M

LTM EBITDA $62.0M

EV

$2.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BGI Genomics Financials

As of September 2025, BGI Genomics reported last 12-month revenue of $513M and EBITDA of $62.0M.

In the same period, BGI Genomics generated $230M in LTM gross profit and -$22.5M in net income.

See BGI Genomics valuation multiples based on analyst estimates

BGI Genomics P&L

In the most recent fiscal year, BGI Genomics reported revenue of $542M and EBITDA of -$49.2M.

BGI Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BGI Genomics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$513M	XXX	$542M	XXX	XXX	XXX
Gross Profit	$230M	XXX	$225M	XXX	XXX	XXX
Gross Margin	45%	XXX	41%	XXX	XXX	XXX
EBITDA	$62.0M	XXX	-$49.2M	XXX	XXX	XXX
EBITDA Margin	12%	XXX	-9%	XXX	XXX	XXX
EBIT	-$19.9M	XXX	-$57.4M	XXX	XXX	XXX
EBIT Margin	-4%	XXX	-11%	XXX	XXX	XXX
Net Profit	-$22.5M	XXX	-$127M	XXX	XXX	XXX
Net Margin	-4%	XXX	-23%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for BGI Genomics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $513M. EBITDA for the last twelve months was $62.0M. In the most recent fiscal year, BGI Genomics achieved $542M in revenue and -$49.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$513M	Analyst estimates available to subscribers	$542M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$230M	Analyst estimates available to subscribers	$225M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	44.9% gross margin	Analyst estimates available to subscribers	41.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$62.0M	Analyst estimates available to subscribers	-$49.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	12.1% EBITDA margin	Analyst estimates available to subscribers	-9.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$19.9M	Analyst estimates available to subscribers	-$57.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-3.9% EBIT margin	Analyst estimates available to subscribers	-10.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$22.5M	Analyst estimates available to subscribers	-$127M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-4.4% net profit margin	Analyst estimates available to subscribers	-23.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for BGI Genomics

This financial data table provides comprehensive performance metrics for BGI Genomics, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

BGI Genomics generated $513M in revenue over the last twelve months.
The company achieved $62.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $230M.
Net income over the last twelve months reached -$22.5M.

Fiscal Year Performance

In the most recent fiscal year, BGI Genomics reported $542M in total revenue.
Fiscal year EBITDA was -$49.2M.
The company maintained a gross profit margin of 41.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was -9.1%.
Net profit margin reached -23.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for BGI Genomics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

BGI Genomics Stock Performance

BGI Genomics has current market cap of CNY 19.5B (or $2.7B), and EV of CNY 16.3B (or $2.3B).

Market Cap Evolution

BGI Genomics Stock Data

As of October 17, 2025, BGI Genomics's stock price is CNY 47 (or $7).

See BGI Genomics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.3B	$2.7B	XXX	XXX	XXX	XXX	$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

BGI Genomics Valuation Multiples

BGI Genomics's trades at 4.2x EV/Revenue multiple, and -46.4x EV/EBITDA.

See valuation multiples for BGI Genomics and 15K+ public comps

BGI Genomics Financial Valuation Multiples

As of October 17, 2025, BGI Genomics has market cap of $2.7B and EV of $2.3B.

Equity research analysts estimate BGI Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BGI Genomics has a P/E ratio of -121.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.7B	XXX	$2.7B	XXX	XXX	XXX
EV (current)	$2.3B	XXX	$2.3B	XXX	XXX	XXX
EV/Revenue	4.5x	XXX	4.2x	XXX	XXX	XXX
EV/EBITDA	36.8x	XXX	-46.4x	XXX	XXX	XXX
EV/EBIT	-114.6x	XXX	-39.8x	XXX	XXX	XXX
EV/Gross Profit	9.9x	XXX	n/a	XXX	XXX	XXX
P/E	-121.4x	XXX	-21.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-37.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BGI Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

BGI Genomics Margins & Growth Rates

BGI Genomics's last 12 month revenue growth is 7%

BGI Genomics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

BGI Genomics's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BGI Genomics's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BGI Genomics and other 15K+ public comps

BGI Genomics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	7%	XXX	2%	XXX	XXX	XXX
EBITDA Margin	12%	XXX	-9%	XXX	XXX	XXX
EBITDA Growth	53%	XXX	-7%	XXX	XXX	XXX
Rule of 40	22%	XXX	-2%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	31%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	16%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial